Disease Management Program Cost Savings Not Yet Demonstrated, CBO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While studies show such programs improve control of diseases, the net effect on health costs is not clear, a Congressional Budget Office report says. Translating successful disease management results to the Medicare population could be difficult, the report notes.
You may also be interested in...
Disease Management Will Yield More Savings In Medicare Than Private Plans, CMS Says
Medicare beneficiaries offer a more stable population with a greater number of chronic diseases than those in private plans, CMS’ Guterman says. Current expectations about possible returns on investment from disease management programs are too high, Disease Management Purchasing Consortium says.
Disease Management Will Yield More Savings In Medicare Than Private Plans, CMS Says
Medicare beneficiaries offer a more stable population with a greater number of chronic diseases than those in private plans, CMS’ Guterman says. Current expectations about possible returns on investment from disease management programs are too high, Disease Management Purchasing Consortium says.
Disease Management Valuable Despite CBO Findings, Industry Group Says
Congressional Budget Office’s study finding lack of evidence to conclude programs save money was based on old data and was not comprehensive, Disease Management Association of America President Nussbaum says. The Anthem exec cites study data showing disease management resulted in a 14% reduction in medical costs.